Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $1 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.5% | 85.9% | 52.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 86% | 86.9% | 83.9% | 84.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 47.4% | 30.1% | 48.1% | 37.3% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 33.3% | 17.9% | 38.8% | 28% |
| EPS Diluted | 1.31 | 0.63 | 0.75 | 0.37 |
| % Growth | 107.9% | -16% | 102.7% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |